Analysts’ recommendations and target price
Boston Scientific (BSX) is scheduled to post its fourth-quarter and 2018 earnings results on February 6, 2019.
In this article, we’ll discuss analysts’ ratings and target price for Boston Scientific as well as the company’s share price fluctuations just ahead of its fourth-quarter results.
The 12-month consensus analyst recommendation for Boston Scientific as of January 30 is a “strong buy.” The 12-month consensus target price for the company is $42.22, which is 14.08% higher than its closing price on January 29. The highest, median, and lowest target price estimates for the company are $46, $42, and $37, respectively.
Of the 24 analysts covering Boston Scientific on January 30, 15 have rated the company as a “strong buy,” seven have rated it as a “buy,” and two have rated it as a “hold.”
Share price movements
On January 29, Boston Scientific closed at $37.01, 0.43% higher than its previous closing price. The company closed at a premium of 47.80% to its 52-week low of $25.04 and at a discount of 6.16% to its 52-week high of $39.44. On January 29, Boston Scientific’s market cap was $51.18 billion. The company was trading at a trailing PE ratio of 33.92x and a forward PE ratio of 23.42x.
Based on its closing price on January 29, the company had reported returns of -0.67% in the last week, 7.34% in the last month, and 1.70% in the last quarter. It had also reported returns of 9.59% in the last half year, 30.23% in the last year, and 4.73% YTD (year-to-date).
Based on its closing price on January 29, the broader medical device market represented by the iShares US Medical Devices ETF (IHI) had reported returns of -1.16% in the last week, 5.79% in the last month, and 1.46% in the last quarter. IHI had also reported returns of -0.07% in the last half year, 7.11% in the last year, and 3.83% YTD.
Boston Scientific has outperformed IHI YTD.
In the next article, we’ll discuss revenue estimates for Boston Scientific in the fourth quarter and 2018 in greater detail.